| HIC3 | HIC3 Description |
| V1A | ALKYLATING AGENTS |
| V1B | ANTIMETABOLITES |
| V1C | VINCA ALKALOIDS |
| V1D | ANTIBIOTIC ANTINEOPLASTICS |
| V1E | STEROID ANTINEOPLASTICS |
| V1F | ANTINEOPLASTICS,MISCELLANEOUS |
| V1G | RADIOACTIVE THERAPEUTIC AGENTS |
| V1H | ANTINEOPLASTICS,MISCELLANEOUS (CONTINUED 1) |
| V1I | CHEMOTHERAPY RESCUE/ANTIDOTE AGENTS |
| V1J | ANTIANDROGENIC AGENTS |
| V1K | ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES |
| V1L | VASCULAR OCCLUSIVE AGENTS,ANTINEOPLASTIC ADJUVANT |
| V1M | ANTINEOPLASTIC IMMUNOMODULATOR AGENTS |
| V1N | SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR) |
| V1O | ANTINEOPLASTIC LHRH(GNRH) AGONIST,PITUITARY SUPPR. |
| V1P | TUMOR NECROSIS FACTOR AGENTS |
| V1Q | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| V1R | PHOTOACTIVATED, ANTINEOPLASTIC AGENTS (SYSTEMIC) |
| V1S | INTRAPLEURAL, SCLEROSING AGENTS, ANTINEOPLAST. ADJ. |
| V1T | SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM) |
| V1U | ANTINEOPLASTIC ANTIBODY/RADIOACTIVE-DRUG COMPLEXES |
| V1V | ANTINEOPLASTIC LHRH(GNRH) ANTAGONIST,PITUIT.SUPPRS |
| V1W | ANTINEOPLASTIC EGF RECEPTOR BLOCKER RCMB MC ANTIBODY |
| V1X | ANTINEOPLASTIC HUM VEGF INHIBITOR RECOMB MC ANTIBODY |
| V1Y | ALKYLATING AGENTS (CONTINUED 1) |
| V1Z | ANTIMETABOLITES (CONTINUED 1) |
| V2A | NEOPLASM MONOCLONAL DIAGNOSTIC AGENTS |
| V3A | ANTINEOPLASTIC, HISTONE DEACETYLASE (HDAC) INHIBITORS |
| V3B | ANTIANDROGEN -ANTINEOPLASTIC LHRH (GNRH) AGNST, PITUITARY SUPPR. |
| V3C | ANTINEOPLASTIC - MTOR KINASE INHIBITORS |
| V3D | ANTINEOPLASTIC - EPOTHILONES AND ANALOGS |
| V3E | ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS |
| V3F | ANTINEOPLASTIC - AROMATASE INHIBITORS |
| V3G | ENZYME INHIBITORS, ANTINEOPLASTIC ADJUVANTS |
| V3H | ANTINEOPLASTIC - IMMUNOTHERAPY, THERAPEUTIC VAC |
Return to Drug Specific Therapeutic Class Codes and Descriptions